Full-Time

Data Governance & Data Quality Specialist

Posted on 7/4/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

On-site role in Hyderabad, India; relocate not specified.

Bachelor's, Master's

Category
Data & Analytics (1)
Required Skills
Python
SQL
Collibra
Data Governance

Get referred to Amgen

See people who can refer or advise you

Requirements
  • Master’s / Bachelor’s degree with 9 - 12 years of experience in Data Science, Artificial Intelligence, Computer Science, or related fields
  • Technical skills (Advanced SQL, Python) with knowledge of Pharma processes with specialization in a domain (e.g., Research, Clinical Trials, Commercial, etc.)
  • In depth experience of working with or supporting systems used to data governance framework. E.g. Collibra, Alation
  • In depth knowledge of data management, common data models, metadata management, data quality, master data management, data stewardship, data protection, etc.
  • In depth experience with data products development life cycle, including the enablement of data dictionaries, business glossary to increase data products reusability and data literacy.
  • Customer focused with excellent written and verbal communication skills who can confidently work with internal Amgen business stakeholders and external service partners on business process and technology topics
  • Ability to manage scrum teams
Responsibilities
  • Responsible for the adoption of data governance framework implementation for a given domain of expertise (Research, Development, Supply Chain, etc.).
  • Responsible for the operationalization of the Enterprise data governance framework and aligning broader stakeholder community with their data governance needs, including data quality, data access controls, compliance with privacy and security regulations, foundational master data management, data sharing, communication and change management.
  • Works with Enterprise MDM and Reference Data to enforce standards and data reusability.
  • Drives cross functional alignment in his/her domain(s) of expertise to ensure adherence to Data Governance principles.
  • Develops policies for data, metadata, privacy, lineage, access, security, retention, and archival.
  • Maintain documentation on data definitions, data standards, data flows, legacy data structures / hierarchies, common data models, data harmonization etc. for assigned domains.
  • Ensure compliance requirements with data privacy, security, and regulatory policies for the assigned domains
  • Jointly with Technology teams, business functions, and enterprise teams (e.g., MDM, Enterprise Data Fabric, etc.) define the specifications shaping the development and implementation of data foundations
  • Build strong relationship with key business leads and partners to ensure their needs are met
Desired Qualifications
  • Experience of working with data governance councils or forums
  • Experience with Agile software development methodologies (Scrum)
  • Excellent analytical skills
  • Ability to work effectively with global, virtual teams
  • Ability to manage multiple priorities successfully
  • Team-oriented, with a focus on achieving team goals
  • Ability to build business relationships and understand end-to-end data use and needs.
  • Excellent interpersonal skills (team player). People management skills either in matrix or direct line function.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion; guidance increased to $38.2-$39.4 billion.
  • Repatha grew 37%, Evenity 38%, and Uplizna 90% in Q2 2026.
  • Colorado’s Enbrel price cap was blocked on July 1, 2026, preserving legacy cash flow.

What critics are saying

  • FDA proposed Tavneos withdrawal on April 27, 2026; a hearing loss kills ChemoCentryx economics.
  • Tavneos retraction and liver-injury findings threaten Amgen’s credibility with regulators and investigators in 2026.
  • Prolia erosion and patent battles, including Delaware’s June 2026 verdict, pressure margins until 2027.

What makes Amgen unique

  • MariTide’s monthly-to-quarterly dosing targets obesity convenience versus weekly GLP-1 rivals in 2027.
  • Amgen’s 2026 base is unusually diversified: Repatha, Evenity, Uplizna, Tezspire, and Imdelltra.
  • Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-linked discovery capacity globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.

PR Newswire
Aug 4th, 2026
Amgen reports 10% revenue growth to $10.1B in Q2 2026, driven by 26% surge in six key growth products

Amgen reported second quarter 2026 revenues of $10.1 billion, a 10% increase year-over-year. Product sales grew 9%, driven by volume growth across 22 products that achieved double-digit sales growth. The company's six key growth drivers grew 26% year-over-year, generating nearly 70% of second quarter product sales. GAAP earnings per share increased 65% to $4.37, whilst non-GAAP EPS rose 4% to $6.29. Notable product performance included Repatha sales increasing 37% to $953 million and EVENITY growing 38% to $714 million. The company generated $3.5 billion in free cash flow, compared to $1.9 billion in the prior year period. For full year 2026, Amgen expects total revenues between $38.2 billion and $39.4 billion, with non-GAAP EPS guidance of $22.30 to $23.50.

INACTIVE